Table 1.
Patient and treatment characteristics of cohort
| All patients (N = 173) | |
|---|---|
| Age | |
| Median (IQR) | 61 (52-68) |
| Sex | |
| Male | 77 (44.5%) |
| Female | 96 (55.5%) |
| Race | |
| White | 153 (88.4%) |
| Black | 15 (8.7%) |
| Other | 5 (2.9%) |
| KPS | |
| Median (IQR) | 80 (70-90) |
| GPA | 2 (1.5-2.5) |
| Median (IQR) | |
| Primary tumor site | |
| Lung | 77 (44.5%) |
| Breast | 33 (19.1%) |
| Genitourinary | 9 (5.2%) |
| Melanoma | 24 (13.9%) |
| Head and neck | 3 (1.7%) |
| Gynecologic | 6 (3.5%) |
| Gastrointestinal | 10 (5.8%) |
| Sarcoma | 3 (1.7%) |
| Other | 8 (4.6%) |
| Total no. of SRS courses | |
| Median (range) | 1 (1-9) |
| Total no. of brain metastases treated with SRS | |
| Median (range) | 5 (2-58) |
| All SIMT SRS courses (N = 208) | |
|---|---|
| Dose and fractionation | |
| 18-24 Gy × 1 fraction | 93 (44.7%) |
| 7-9 Gy × 3 fractions | 82 (39.4%) |
| 5-6 Gy × 5 fractions | 33 (15.9%) |
| Beam energy | |
| 6 MV | 109 (52.4%) |
| 6 MV-FFF | 91 (43.8%) |
| 10 MV-FFF | 8 (3.8%) |
| No. of target lesions | |
| Median (range) | 3 (2-30) |
| Prior WBRT | |
| No | 171 (82.2%) |
| Yes | 37 (17.8%) |
Abbreviations: FFF = flattening filter-free; GPA = graded prognostic assessment; IQR = interquartile range; KPS = Karnofsky performance status; SIMT = single-isocenter multitarget; SRS = sterotactic radiosurgery; WBRT = whole brain radiation therapy.